Bristol Myers Squibb Company $BMY Shares Sold by Range Financial Group LLC

Range Financial Group LLC lowered its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 72.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 15,227 shares of the biopharmaceutical company’s stock after selling 40,053 shares during the quarter. Range Financial Group LLC’s holdings in Bristol Myers Squibb were worth $687,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of BMY. Trifecta Capital Advisors LLC purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth about $25,000. Darwin Wealth Management LLC acquired a new position in shares of Bristol Myers Squibb during the second quarter worth about $25,000. Harbor Capital Advisors Inc. grew its position in shares of Bristol Myers Squibb by 107.2% during the third quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares in the last quarter. REAP Financial Group LLC raised its holdings in Bristol Myers Squibb by 202.8% in the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 428 shares in the last quarter. Finally, CBIZ Investment Advisory Services LLC lifted its stake in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 231 shares during the last quarter. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of analyst reports. Wells Fargo & Company raised their price objective on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Cantor Fitzgerald restated a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Morgan Stanley reaffirmed an “underweight” rating and set a $37.00 price objective (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 3rd. Six research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $54.62.

Bristol Myers Squibb Stock Down 0.9%

Shares of NYSE BMY opened at $54.15 on Tuesday. The business has a 50-day moving average price of $49.04 and a 200 day moving average price of $47.35. The stock has a market cap of $110.23 billion, a PE ratio of 18.29, a price-to-earnings-growth ratio of 8.36 and a beta of 0.29. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.52 by $0.11. The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a return on equity of 76.53% and a net margin of 12.57%.The firm’s revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Equities research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.7%. The ex-dividend date of this dividend is Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is 83.78%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.